UBS sets USD 673 target for Medpace Holdings stock

Published on 10/05/2026 at 20:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 707.3 million in the second quarter of 2026. Medpace Holdings stock costs EUR 552.30 on October 5, 2026 after EUR 532.70.

MEDP, US58506Q1094, Illustration mit AI erstellt.

Medpace Holdings (ISIN US58506Q1094) was trading at EUR 552.30 at Lang & Schwarz on October 5, 2026 at 8:51 p.m. CEST, plus 3.68 percent versus the EUR 532.70 prior close. The latest analyst action came from UBS, which began coverage on September 30, 2026 with a Neutral rating and a USD 673.00 price target, according to GuruFocus.

UBS balances growth with valuation

UBS's Neutral stance contrasts with the USD 673.00 target, while the stock's euro quote provides a separate German-market reference for the session. GuruFocus said UBS based its view on contract research organization sector growth expectations and Medpace's valuation.

Second-quarter revenue rose 17.20 percent

Medpace reported revenue of USD 707.3 million for the second quarter of 2026, up 17.20 percent from USD 603.3 million a year earlier, according to Business Wire. MarketBeat reported adjusted earnings of USD 4.25 per share against a USD 3.98 consensus estimate for the same quarter.

The comparison matters because the revenue increase was paired with an earnings surprise of USD 0.27 per share. Medpace's business model spans clinical development services for biotechnology, pharmaceutical and medical device companies, from Phase I through Phase IV, according to the company's investor materials at Medpace.

Third-quarter results are scheduled

Medpace will report third-quarter 2026 financial results after the market close on October 21, 2026, with a conference call scheduled for October 22, 2026 at 9:00 a.m. ET, according to Business Wire. That date gives investors the next scheduled checkpoint for bookings, revenue growth and the outlook.

MEDP gains in after-hours trading

Medpace Holdings stock was trading at EUR 552.30 at Lang & Schwarz on October 5, 2026 at 8:51 p.m. CEST, plus 3.68 percent versus the prior close of EUR 532.70 on October 2, 2026. The primary listing is Nasdaq in USD, while the euro quote remains the reference for this article.